
Bavarian Nordic cannot exclusively handle production of the company's covid-19 vaccine if and when it is ready for phase III and the subsequent commercialization.
In spite of expansions made in the firm's production apparatus in recent years, the firm lacks the equipment and capacity necessary for fulfilling production in this scale, which Bavarian Nordic Chief Financial Officer Henrik Juuel tells MedWatch in an interview.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app